Laboratory Glassware Market worth $9,170 million by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets forecasts the global laboratory glassware market to grow from $7.63B in 2026 to $9.17B by 2031, a 4.0% CAGR, supported by pharmaceutical, biotechnology, clinical-testing and academic research demand. Plasticware represented 68% of the market in 2025 and is expected to be the fastest-growing product category, while Asia Pacific is projected to deliver the strongest regional growth. The fragmented supplier base, including Corning, Thermo Fisher, Eppendorf and Sartorius, leaves scope for partnerships, geographic expansion and consolidation.

Analysis

This is not a market-moving demand signal for TMO, GLW, AVTR, or SRT3: the addressed consumables pool is small relative to their group revenues, and the forecast is from a market-study vendor rather than a customer order, tender, or reported backlog. The investable implication is mix, not top-line acceleration. Recurring single-use workflows support steadier consumables revenue and potentially better visibility, but price competition in fragmented, distributor-led categories limits the likelihood of material gross-margin expansion.

GLW is the cleanest listed read-through where specialized vessels, cell-culture formats, and regional manufacturing localization can add to life-sciences mix; however, a broad shift toward low-cost plastic consumables is more favorable to scaled catalog/distribution platforms such as AVTR and TMO than to glass-focused suppliers. DKSH has a more direct near-term opportunity from Asian distribution density and vendor consolidation, but its economics depend on preserving principal relationships and working-capital discipline; revenue growth without improved inventory turns would not justify multiple expansion.

Over 1-3 months, the relevant catalysts are reported bioprocessing/clinical-research order trends, China and Southeast Asia pharma-capex indicators, and evidence that academic funding converts into procurement. Over 6-18 months, localized manufacturing can reduce freight and stockout risk but may also create regional pricing pressure and duplicate fixed costs. The contrarian view is that the market is already mature and largely nondiscretionary: a modest volume tailwind may be offset by procurement standardization, private-label substitution, and pressure on distributors to pass through savings rather than retain them.

Key Decisions for Investors

• No directional trade solely on this release; treat it as a watch item. Require next-quarter consumables organic growth, segment margin, and order/backlog commentary from TMO, AVTR, and GLW before underwriting an earnings revision.
• Maintain a 6-12 month relative preference for TMO over AVTR: TMO has broader exposure to automated workflows, instruments, and service pull-through, while AVTR is more exposed to distributor/private-label competition. Falsify if AVTR delivers two consecutive quarters of faster organic consumables growth with stable or rising gross margin.
• For GLW, use weakness following a soft Display or Optical Communications print to build a small life-sciences-mix position rather than chase this theme. Upside requires Life Sciences growth to reaccelerate above the corporate base; exit if segment sales remain flat-to-down despite broader laboratory demand improvement.
• Monitor DKSH for a tactical 3-6 month long only if Thailand/Eppendorf integration discloses incremental revenue and inventory turns hold. A deterioration in net working capital, loss of exclusivity, or margin dilution would invalidate the distribution-expansion thesis.